ClinicalTrials.gg
RecruitingNCT06206083Updated Feb 28, 2024

Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis

An observational study in Endometrial Cancer, sponsored by National Institute of Cancerología. Recruiting at 1 site in Mexico. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by National Institute of Cancerología · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
64
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Endometrial Neoplasms with a site in Mexico — 4 open to participants now, 7 under way, 4 of them phase 3. Endometrial Neoplasms · Mexico.

Started
2024
with 1 other
Observational
Only one
of the 10
Registered
7th of 10
by date
Lead sponsor
2 of 10
National Institute of Cancerología

Among the 10 studies in Endometrial Neoplasms with a site in Mexico, this one is one of 2 that started in 2024, is the only observational one, and was the 7th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

4 of the 10 studies in Endometrial Neoplasms with a site in Mexico are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Endometrial Neoplasms with a site in Mexico, or all of them as a file.
02

Study summary

Endometrial cancer (EC) is one of the most common gynecological neoplasms, being the second in incidence and third in mortality in Mexico. Recent studies show that EC molecular classification (Cancer Genome Atlas Research Network, 2013) serves to establish a more accurate prognosis in these patients and regulate therapeutic behavior in a personalized manner. However, there are no studies on EC molecular classification in Mexican women or its impact on prognosis and the possible modification of targeted treatment. The investigators will determine the molecular classification in EC by next-generation sequencing (NGS) to detect TP53 and POLE somatic mutations, and immunohistochemical detection of microsatellite instability (MSH2, MLH1, PMS1, PMS2, MSH6, and MSH3) in a cohort of patients with endometrioid-type EC, endometrioid subtype, attended at the Instituto Nacional de Cancerología - Mexico (INCan) and determine its impact on clinical prognosis.

Read the detailed description

The investigators will carry out a pilot study on patients with endometrioid type EC treated between 2015-2019. Samples of patients over 18 years of age admitted to the cohort with a diagnosis of endometrioid-type EC are already collected and will be evaluated for exome sequencing (N=32) and the detection of POLE mutations. DNA will be extracted using the "DNA/RNA AllPrep" kit (QIAGEN). Verification of adequate DNA extraction will be performed by quantifying using TapeStation (Agilent). Exome sequencing (N = 32 tumor samples and 32 somatic samples [leukocytes] from the same patient) will be carried out using Illumina's Nextera Rapid Capture Exome at Azenta Life Science (NJ, USA) following preset protocols and with a depth of 100X. The alignment and detection of variants will be done with the GATX-Mutect Suite (Broad Institute, USA) and the annotation of variant filtering with ANNOVAR. The identification of hotspots will be made according to Chen study. The immunohistochemistry (IHC) for microsatellite instability and overexpressed mutant TP53 (N = 94) will be done using established IHC protocols and will include MSH2, MLH1, PMS1, PMS2, MSH6, MSH3, and TP53.

03

Conditions studied

  • Endometrial Cancer

Keywords

  • Endometrial cancer
  • Prognostic factors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

The investigators will evaluate samples from patients with endometrioid type EC treated between 2015-2019. Samples of patients over 18 years of age admitted to the cohort with a diagnosis of endometrioid-type EC are already collected and will be evaluated for exome sequencing (N=32) for the detection of POLE mutations.

Eligibility criteria

Criteria: Inclusion Criteria:

  • Clinical diagnosis of endometrioid-type endometrial cancer with samples available
  • That the patients have undergone surgery at INCan.

Exclusion Criteria:

  • Samples with CEE of non-endometroid type.
  • Samples from patients with double primary neoplasm, including carcinoma ductal in situ, squamous cell skin cancers, and cervical carcinoma in situ
  • History of \< 5 years prior with no evidence of disease (i.e., remission).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
64 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with EC endometroid

    Patients with EC endometroid subtype and peripheral blood, treated during 2015-2019 at the INCan.

    Genetic: Descriptive and analytical

Interventions

  • GeneticDescriptive and analytical

    Patients with EC endometroid

06

What researchers measure

Primary outcomes

  1. sequence the exome

    Molecular classification of endometroid-type endometrial cancer in Mexican participants based on POLE and TP53 mutations as well as makers of microsatellite instability (MSH2, MLH1, PMS1, PMS2, MSH6, and MSH3).

    Time frame: 2024-2025

  2. Determine POLE mutations

    Determine POLE mutations by massive next-generation sequencing of a discovery cohort in patients with endometroid-type EC.

    Time frame: 2024-2025

  3. Determine microsatellite instability

    To perform validation of POLE mutation by real-time PCR in a validation cohort of patients with endometroid-type EC.

    Time frame: 2025-2026

  4. Validation

    To perform validation of POLE mutation by real-time PCR in a validation cohort of patients with endometroid-type EC.

    Time frame: 2025-2026

Secondary outcomes

  1. Overall survival

    To describe the overall survival of molecular types of endometroid-type EC in INCan patients.

    Time frame: 2025-2026

  2. Disease-free surviva

    To describe the disease-free survival of the molecular types of endometroid-type EC in INCan patients.

    Time frame: 2025-2026

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: Any time by direct request to the principal investigator

Access criteria: Only for research purposes.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2024; primary completion for Nov 2026, 32 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2023
First posted
Jan 16, 2024
StartEst.
Mar 1, 2024
Primary completionEst.
Nov 1, 2026
CompletionEst.
Feb 1, 2027
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06206083
Lead sponsor
National Institute of Cancerología
Collaborators
GlaxoSmithKline
Responsible party
David Cantu (Doctor in Medical Sciences; Researcher in Medical Sciences, National Institute of Cancerología) — Principal investigator
First posted
Jan 16, 2024
Start date
Mar 1, 2024 (estimated)
Primary completion
Nov 1, 2026 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Feb 28, 2024

Study contacts

David F Cantu-de-León, PhD
Contact
dfcantu@gmail.com
+52-55-5628-0400 ext. 21016
Diddier Prada, PhD
Contact
pradadiddier@gmail.com
+52-55-41-42-18-02
David F Cantu-de-León, PhD
principal investigator · The Principal Investigator

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion